Pharminent

Pfizer spinoff Zoetis ups 2017 guidance, eyes more M&A for future growth

What does Pfizer animal health spinoff Zoetis share with its former parent, aside from its lineage? They’re both under pressure from investors to drive growth through acquisitions. Zoetis met second-quarter expectations and brightened its forecast for the rest of the year, and now it’s looking to M&A to drive further growth. http://www.fiercepharma.com/financials/pfizer-spinoff-zoetis-ups-2017-guidance-eyes-m-a-for-future-growth

Filed under: Company